InsideArbitrage Potential Deal Alert: Reneo Pharmaceuticals (RPHM) approached by Concentra Biosciences

According to the 13D filing, Reneo Pharmaceuticals (RPHM) received a non-binding takeover proposal from Concentra Biosciences for $1.80 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds payable from any license or disposition of Reneo’s programs.

Reneo Pharmaceuticals Investor Relations